id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2009-E-0087-0007,FDA,FDA-2009-E-0087,Pfizer Inc. - Letter,Other,Letter(s),2011-07-14T04:00:00Z,2011,7,2011-07-14T04:00:00Z,,2011-07-14T22:27:14Z,,0,0,0900006480ec098a
FDA-2009-E-0087-0006,FDA,FDA-2009-E-0087,FDA/CDER to U.S. Patent and Trademark Office - Letter,Other,LET-Letter,2011-05-04T04:00:00Z,2011,5,2011-05-04T04:00:00Z,,2011-05-04T16:05:50Z,,0,0,0900006480c3f322
FDA-2009-E-0087-0005,FDA,FDA-2009-E-0087,Determination of Regulatory Review Period for Purposes of Patent Extensions; CONVENIA,Notice,N-Notice,2011-04-29T04:00:00Z,2011,4,2011-04-29T04:00:00Z,2011-06-29T03:59:59Z,2011-04-29T14:06:21Z,2011-10379,0,0,0900006480c3be4e